Pfizer

pharmaNew York
Trials 0
Subs 0
People 0
Links 11

Executive Summary

This appears to be incomplete or erroneous data - Pfizer is a major US pharmaceutical company headquartered in New York, not a Chinese entity. Pfizer has no BIOSECURE risk as it's an American multinational corporation. If evaluating the actual Pfizer Inc., they would be a potential partner rather than acquisition target, with strong pipeline capabilities across oncology, vaccines, and rare diseases.

Structure: Data inconsistency detected - Pfizer Inc. is a US publicly traded company (NYSE: PFE) with standard Delaware corporation structure. If this refers to a different Chinese entity with similar naming, corporate structure details are not available in the provided data.

Ownership & Shareholder Structure

3SBio Pfizer

deal_partner

Pfizer-3SBio $4.8B bispecific antibody ($1.25B upfront).

Zai Lab Pfizer

personnel

Samantha Du (Zai Lab founder) was former VP at Pfizer.

Hutchmed Pfizer

personnel

Weiguo Su (HUTCHMED CEO) was former VP at Pfizer.

CStone Pharmaceuticals Pfizer

deal_partner

CStone-Pfizer sugemalimab collaboration for oncology in China.

Insilico Medicine Pfizer

deal_partner

Insilico AI drug discovery collaboration with Pfizer.

Simcere Pharmaceutical Pfizer

deal_partner

Simcere licensed Pfizer products for China distribution.

WuXi AppTec Pfizer

cdmo_client

WuXi AppTec provides CDMO services to Pfizer. Key API manufacturing relationship.

Asymchem Laboratories Pfizer

cdmo_client

Asymchem manufactured Paxlovid API for Pfizer. Key CDMO relationship.

Tigermed Pfizer

cdmo_client

Tigermed provides CRO services to Pfizer for China clinical trials.

Pharmaron Pfizer

cdmo_client

Pharmaron provides drug discovery CRO services to Pfizer.

Porton Pharma Solutions Pfizer

cdmo_client

Porton provides intermediate manufacturing to Pfizer.

BIOSECURE Risk

low

If referring to US Pfizer Inc., no BIOSECURE risk as it's an American company. If referring to a Chinese entity, insufficient data to assess risk properly.

Mitigation: Not applicable for US Pfizer Inc.

BD Intelligence

Pipeline Strength0/10
Deal Readiness0/10

Therapeutic Areas:

Recent Deals: No data available - entity information appears incomplete or incorrect

Approach: Clarify entity identity before proceeding - data suggests confusion between US Pfizer Inc. and unknown Chinese entity

Red Flags

  • Entity data inconsistency - Chinese company classification with US pharma giant name
  • No key personnel data available
  • No subsidiary information provided
  • No recent corporate events recorded
  • Missing ticker symbol despite apparent public company status

Quick Facts

Key People
0
Subsidiaries
0
CDMO/CRO Subs
0
Genomics Subs
0
Direct BIOSECURE
0
Corp Events
0
Gov-Connected
0
Clinical Trials
0
Publications
0
Drug Molecules
0
Relationships
11

Sources & Methodology

Clinical trials data: ClinicalTrials.gov API v2 (0 trials linked to this entity)

SEC BIOSECURE filings: EDGAR EFTS full-text search (850+ filings from 230 companies)

Publications: Europe PMC API (0 publications indexed)

Drug molecules: ChEMBL database (European Bioinformatics Institute)

Financial data: East Money (东方财富) datacenter API / CNINFO (巨潮资讯网)

Corporate structure: Company official filings, HKEX/SSE/SZSE disclosures

Executive profiles: Company official biographies, SEC filings, LinkedIn (where verified)

Data is collected from public sources and updated weekly. Corporate intelligence is verified by a native Mandarin-speaking analyst against Chinese-language primary sources including Tianyancha (天眼查), GSXT (国家企业信用信息公示系统), and CNINFO (巨潮资讯网). This is not financial or legal advice.